New cord blood treatment shows promise for tough leukemia cases

NCT ID NCT03913026

Ongoing Disease control Sponsor: Ciusss de L'Est de l'Île de Montréal Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase II trial tests a new way to use cord blood transplants for people with high-risk acute leukemia or myelodysplasia. The cord blood is treated with a molecule called UM171 to increase the number of stem cells, which may help the transplant work better and reduce serious side effects. The study includes 30 participants and aims to see if this approach lowers transplant-related deaths and improves survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: UM171-expanded cord blood transplant
What this could lead to: If successful, this could offer a safer and more effective stem cell transplant option for people with high-risk blood cancers, potentially improving survival and reducing transplant-related deaths.
What could go wrong: This is a small, early-phase trial with only 30 participants, so results may not apply to everyone. There are still risks of infection, graft failure, or relapse, and long-term outcomes are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute lymphoblastic leukemia acute myeloid leukemia myelodysplastic syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CORD BLOOD TRANSPLANT HIGH RISK HEMATOLOGIC MALIGNANCY

Contacts and locations

Locations

CIUSSS de l'Est-de-l'île-de Montreal, Hôpital Maisonneuve-Rosemont

Montreal, Quebec, H1T2M4, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.